Molecular therapy for Metabolic disorders: MiRNA-744 increases insulin-secreting cell mass and function via down regulation of its target genes, 19/November/2016, 10.33 am

Anti-metastasis therapy: MiRNA-9600 increases the expression of PDCD4 and inhibits migration, invasion and metastasis of cancer cells via down regulation of its target gene, 19/November/2015, 10.15 am
November 19, 2016
Molecular therapy for tuberculosis: MiRNA-429 increases the expression of MKP-1, inhibits TLR2 signalling, secretion of Chemokine CXCL5, and recruitment of polymorphonuclear leukocytes (PMNs), decreases destructive pulmonary inflammation, promotes M. tuberculosis clearance and inhibits pulmonary tuberculosis via up-regulation of its target gene, 19/November/2016, 10.23 pm
November 19, 2016
Show all

Significance of the study: 

Given that (1)  more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) the life-long painful injection/drug treatment required to treat DM; and (3) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i)  a way to induce regeneration of adult β-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free natural product-based drug.


From research findings to therapeutic opportunity:

This study suggests an MiRNA-based Regenerative therapy for DM.  MiRNA-744by increasing the expression of its target gene it may: (1) increase the expression of modulator of lipid homeostasis liver X receptor (LXR)-α; (2) decrease plasma levels of triglyceride and cholesterol; (3) protect against diet-induced weight-gain; and (4) increase insulin-secreting cell mass and function. price-50

Thereby, it may increase insulin sensitivity  and leanness.  Thus, pharmacological formulations encompassing “MiRNA-744 or its activators”  can be used to treat metabolic disorders, including DM.


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed information: How MiRNA-744 increases (LXR)-α expression and insulin-secreting cell mass and function. 


References:

CitationBoominathan, L., Molecular therapy for Metabolic disordersMiRNA-744  increases insulin-secreting cell mass and function via down regulation of its target genes, 19/November/2016, 10.33 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.